Faculty


Dr. Kamna Srivastava

Assistant Professor

Molecular Cardiology Lab
Email: kamstav@yahoo.com Kamna_srivastava@hotmail.com

Dr Kamna Srivastava did her B. Pharm, M. Pharm and PhD from Department of Pharmacology, Institute of Technology from Bananas Hindu University. She has past experience by working at National Institute of Immunology, New Delhi as a Pool-Officer under a CSIR guided project after which she joined All India Institute of Medical Sciences, New Delhi as a postdoctoral fellow.

Areas of Research Interest

Molecular cardiology, Pharmacogenomics, Toxicology and Pharmacology

Cardiovascular diseases (CVD) are one of the major causes of mortality worldwide. Based on their antioxidant and inflammatory potential, candidate genes associated with cardiovascular diseases including various isoforms of Heat Shock Proteins, microRNAs, PCSK9 and various novel biomolecules, our lab is working on developing these molecules in to non-invasive and more effective circulating prognostic biomarkers as compared to the already existing markers used in CVD prognosis and diagnosis. Our laboratory has studied extensively the role of gene and proteins encoding Renin Angiotensin Aldosterone system on blood pressure control with ACE inhibitors in north Indian subjects with essential hypertension.

Presently, lab focuses on studying the regulatory function and signaling crosstalk mediated by small non coding RNAs (sncRNAs) such as miRNAs in coronary artery disease (CAD) and to develop these non-coding RNAs as therapeutic targets as well as potential biomarkers in cardiovascular diseases. In another objective, our laboratory has been studying the role of Heat Shock Proteins gene polymorphisms, expression in whole blood and their correlation with plasma inflammatory markers in North Indian subjects with cardiovascular disorders. In a recent effort to develop biomarker based on lipid parameters, our lab is looking into the pathophysiological mechanism of PCSK9 inhibitors in patients with CAD.

Ongoing Projects:

  1. 1. To study the genetic polymorphism of PCSK9 and their expression at molecular levels in patients with coronary artery disease. (DST-2017-2020)

Selected Recent Publications:

  1. 01. Aggarwal, S., Narang, R., Saluja, D., & Srivastava, K. (2024). Diagnostic potential of SORT1 gene in coronary artery disease. Gene, 909, 148308.

  2. 02. Samra, M., & Srivastava, K. (2023). Non-coding RNA and their potential role in cardiovascular diseases. Gene, 851, 147011.

  3. 03. Srivastava, K., Aggarwal, S., Narang, R., &Saluja, D. (2022). PCSK9 A/G (rs505151) Gene Polymorphism and its Expression at the Molecular Level in Patients with Coronary Artery Disease. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 19(2), 66-76.

  4. 04. Kumar, D., Narang, R., Saluja, D., & Srivastava, K. (2022). Functional association of miR-133b and miR-21 through novel gene targets ATG5, LRP6 and SGPP1 in coronary artery disease. Molecular Diagnosis & Therapy, 26(6), 655-664.

  5. 05. Srivastava, K., & Singh, M. K. (2021). Drug repurposing in COVID-19: a review with past, present and future. Metabolism Open, 12, 100121.

  6. 06. Srivastava, K. (2020). Association between COVID-19 and cardiovascular disease. IJC Heart & Vasculature, 29, 100583.

  7. 07. Srivastava, K., Narang, R., Bhatia, J., &Saluja, D. (2020). Hemicentin-1 (Gln5345Arg) Gene Polymorphism in Patients with Essential Hypertension. Cardiology and Cardiovascular Medicine, 4(4), 324-333.

  8. 08. Kumar, D., Narang, R., Sreenivas, V., Rastogi, V., Bhatia, J., Saluja, D., &Srivastava, K. (2020). Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes, 11(2), 164.

  9. 09. Srivastava, K., Chandra, S., Narang, R., Bhatia, J., &Saluja, D. (2018). E-selectin gene in essential hypertension: a case-control study. European journal of clinical investigation, 48(1), e12868.

  10. 10. Kamna Srivastava, K. S., & Kirti Tyagi, K. T. (2018). Single nucleotide polymorphisms of microRNA in cardiovascular diseases.